Literature DB >> 18681855

SDHC mutation in an elderly patient without familial antecedents.

Elena López-Jiménez1, José M de Campos, Elena M Kusak, Iñigo Landa, Susanna Leskelä, Cristina Montero-Conde, Luis J Leandro-García, Luis A Vallejo, Beatriz Madrigal, Cristina Rodríguez-Antona, Mercedes Robledo, Alberto Cascón.   

Abstract

Head and neck paragangliomas are usually asymptomatic and benign tumours arising mainly from the carotid body and the vagal, tympanic or jugular glomus. The majority of patients develop sporadic masses, and around 30% of cases harbour germline mutations in one of the succinate dehydrogenase genes: SDHB, SDHC or SDHD. In these hereditary cases, the presence of familial antecedents of the disease, multiplicity/bilaterality, young age at onset, and more recently, presence of gastrointestinal stromal tumours, are main factors to be considered. Here we describe a new mutation (c.256-257insTTT) affecting the SDHC gene in a 60-year-old-patient with a single head and neck paraganglioma, and without familial antecedents of the disease. In silico splice site analysis showed that this variant created a cryptic splice acceptor site and loss of heterozygosity (LOH) supported the pathogenic role of the mutation. Control population analyses did not detect this variant but revealed a novel SDHC polymorphism that exhibited a frequency of 0.3% (3/1020). This latter finding highlights the importance of assessing the clinical relevance of variants of unknown significance by means of analysing sufficient controls. Despite having found a germline mutation in an older, apparently sporadic patient, we consider that the high costs of analysing all susceptibility genes related to the disease support the recommendation of screening for mutations only in patients fulfilling the above criteria.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18681855     DOI: 10.1111/j.1365-2265.2008.03368.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  15 in total

1.  The clinical phenotype of SDHC-associated hereditary paraganglioma syndrome (PGL3).

Authors:  Tobias Else; Monica L Marvin; Jessica N Everett; Stephen B Gruber; H Alexander Arts; Elena M Stoffel; Richard J Auchus; Victoria M Raymond
Journal:  J Clin Endocrinol Metab       Date:  2014-04-23       Impact factor: 5.958

Review 2.  Mitochondrial Complex II: At the Crossroads.

Authors:  Ayenachew Bezawork-Geleta; Jakub Rohlena; Lanfeng Dong; Karel Pacak; Jiri Neuzil
Journal:  Trends Biochem Sci       Date:  2017-02-07       Impact factor: 13.807

Review 3.  Genetics of Cushing's Syndrome.

Authors:  Laura C Hernández-Ramírez; Constantine A Stratakis
Journal:  Endocrinol Metab Clin North Am       Date:  2018-06       Impact factor: 4.741

Review 4.  The 3PAs: An Update on the Association of Pheochromocytomas, Paragangliomas, and Pituitary Tumors.

Authors:  Paraskevi Xekouki; Ana Brennand; Ben Whitelaw; Karel Pacak; Constantine A Stratakis
Journal:  Horm Metab Res       Date:  2018-10-01       Impact factor: 2.936

5.  Succinate dehydrogenase (SDHx) mutations in pituitary tumors: could this be a new role for mitochondrial complex II and/or Krebs cycle defects?

Authors:  Paraskevi Xekouki; Constantine A Stratakis
Journal:  Endocr Relat Cancer       Date:  2012-10-30       Impact factor: 5.678

Review 6.  SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma-paraganglioma syndromes.

Authors:  B Pasini; C A Stratakis
Journal:  J Intern Med       Date:  2009-07       Impact factor: 8.989

Review 7.  MEN1, MEN4, and Carney Complex: Pathology and Molecular Genetics.

Authors:  Marie Helene Schernthaner-Reiter; Giampaolo Trivellin; Constantine A Stratakis
Journal:  Neuroendocrinology       Date:  2015-01-09       Impact factor: 4.914

Review 8.  International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers.

Authors:  Laurence Amar; Karel Pacak; Olivier Steichen; Scott A Akker; Simon J B Aylwin; Eric Baudin; Alexandre Buffet; Nelly Burnichon; Roderick J Clifton-Bligh; Patricia L M Dahia; Martin Fassnacht; Ashley B Grossman; Philippe Herman; Rodney J Hicks; Andrzej Januszewicz; Camilo Jimenez; Henricus P M Kunst; Dylan Lewis; Massimo Mannelli; Mitsuhide Naruse; Mercedes Robledo; David Taïeb; David R Taylor; Henri J L M Timmers; Giorgio Treglia; Nicola Tufton; William F Young; Jacques W M Lenders; Anne-Paule Gimenez-Roqueplo; Charlotte Lussey-Lepoutre
Journal:  Nat Rev Endocrinol       Date:  2021-05-21       Impact factor: 43.330

Review 9.  15 YEARS OF PARAGANGLIOMA: Clinical manifestations of paraganglioma syndromes types 1-5.

Authors:  Diana E Benn; Bruce G Robinson; Roderick J Clifton-Bligh
Journal:  Endocr Relat Cancer       Date:  2015-08       Impact factor: 5.678

10.  Heterogeneous genetic background of the association of pheochromocytoma/paraganglioma and pituitary adenoma: results from a large patient cohort.

Authors:  Judit Dénes; Francesca Swords; Eleanor Rattenberry; Karen Stals; Martina Owens; Treena Cranston; Paraskevi Xekouki; Linda Moran; Ajith Kumar; Christopher Wassif; Naomi Fersht; Stephanie E Baldeweg; Damian Morris; Stafford Lightman; Amar Agha; Aled Rees; Joan Grieve; Michael Powell; Cesar Luiz Boguszewski; Pinaki Dutta; Rajesh V Thakker; Umasuthan Srirangalingam; Chris J Thompson; Maralyn Druce; Claire Higham; Julian Davis; Rosalind Eeles; Mark Stevenson; Brendan O'Sullivan; Phillipe Taniere; Kassiani Skordilis; Plamena Gabrovska; Anne Barlier; Susan M Webb; Anna Aulinas; William M Drake; John S Bevan; Cristina Preda; Nadezhda Dalantaeva; Antônio Ribeiro-Oliveira; Isabel Tena Garcia; Galina Yordanova; Violeta Iotova; Jane Evanson; Ashley B Grossman; Jacqueline Trouillas; Sian Ellard; Constantine A Stratakis; Eamonn R Maher; Federico Roncaroli; Márta Korbonits
Journal:  J Clin Endocrinol Metab       Date:  2014-12-12       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.